Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Update

Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 191,100 shares, an increase of 309.2% from the March 15th total of 46,700 shares. Currently, 1.5% of the shares of the company are sold short. Based on an average daily volume of 94,200 shares, the short-interest ratio is presently 2.0 days.

Analysts Set New Price Targets

Separately, Chardan Capital increased their price objective on Coya Therapeutics from $11.00 to $14.00 and gave the company a "buy" rating in a report on Wednesday, March 20th.

Coya Therapeutics Stock Performance

NASDAQ COYA traded down $0.11 on Wednesday, hitting $9.24. 41,805 shares of the stock traded hands, compared to its average volume of 91,009. The business's fifty day moving average is $8.79 and its two-hundred day moving average is $6.76. Coya Therapeutics has a 12 month low of $3.21 and a 12 month high of $10.69. The firm has a market capitalization of $134.90 million, a price-to-earnings ratio of -11.85 and a beta of 0.80.

Hedge Funds Weigh In On Coya Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. CM Management LLC grew its holdings in Coya Therapeutics by 66.7% during the third quarter. CM Management LLC now owns 100,000 shares of the company's stock valued at $384,000 after purchasing an additional 40,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Coya Therapeutics by 584.0% in the fourth quarter. Vanguard Group Inc. now owns 97,152 shares of the company's stock worth $720,000 after acquiring an additional 82,948 shares during the period. Worth Venture Partners LLC boosted its holdings in shares of Coya Therapeutics by 6.3% in the second quarter. Worth Venture Partners LLC now owns 146,493 shares of the company's stock worth $596,000 after acquiring an additional 8,735 shares during the period. Geode Capital Management LLC bought a new position in shares of Coya Therapeutics in the second quarter worth $238,000. Finally, Potomac Capital Management Inc. bought a new position in shares of Coya Therapeutics in the fourth quarter worth $156,000. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.